Facioscapulo-humeral dystrophy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 34: | Line 34: | ||
==Classification== | ==Classification== | ||
* There are two genetically distinct but clinically similar forms of FSHD- FSHD1 and FSHD2. | |||
** Over 95% of patients have FSHD type 1 (FSHD1), which is characterized by the deletion of large repeated elements on chromosome 4q's long arm (known as the D4Z4 region). | |||
** Healthy individuals typically have more than 10 repeats in this region, while FSHD1 patients have between 1 and 10 repeats. | |||
** A minority of patients have FSHD type 2 (FSHD2), which is caused by a mechanism independent of deletion. | |||
**Both FSHD1 and FSHD2 share a common downstream mechanism, involving loss of methylation in the D4Z4 region and the activation of a normally silenced gene, DUX4 (double homeobox 4). | |||
**It is believed that the derepression of DUX4 leads to disease through a toxic gain-of-function mechanism. | |||
'''Synonyms and related keywords:''' Facio-Scapulo-Humeral Dystrophy, FSH, FMD, FSHD, Muscular Dystrophy, Facioscapulohumeral, Muscular Dystrophy, Landouzy Dejerine | '''Synonyms and related keywords:''' Facio-Scapulo-Humeral Dystrophy, FSH, FMD, FSHD, Muscular Dystrophy, Facioscapulohumeral, Muscular Dystrophy, Landouzy Dejerine | ||
Revision as of 17:59, 11 May 2024
| Facioscapulo-humeral dystrophy |
History
- FSHD was first identified in 1884 by French doctors Louis Landouzy and Joseph Dejerine.
- In their 1886 study, Landouzy and Dejerine highlighted that FSHD runs in families, affecting four generations in one family they studied.
- The clinical features of FSHD were officially described in 1952 after studying a large family in Utah.
- Interest in FSHD grew from around 1980, leading to a better understanding of how the disease varies and its genetic and physiological complexities.
- By the late 1990s, researchers began to identify the specific areas of Chromosome 4 linked to FSHD.
- The DUX4 gene was identified in 1999, recognized for its expression and harmful effects in 2007, and in 2010, researchers unveiled the genetic process behind its expression.
- In 2012, scientists pinpointed the gene commonly mutated in FSHD2.
- By 2019, the initial medication aimed at combating DUX4 expression commenced clinical trials.
- FSHD is also called:
- Landouzy-Dejerine Disease
- Landouzy-Dejerine syndrome
- Erb-Landouzy-Dejerine syndrome
- Landouzy-Dejerine dystrophy or atrophy
- FSHD is also called:
Classification
- There are two genetically distinct but clinically similar forms of FSHD- FSHD1 and FSHD2.
- Over 95% of patients have FSHD type 1 (FSHD1), which is characterized by the deletion of large repeated elements on chromosome 4q's long arm (known as the D4Z4 region).
- Healthy individuals typically have more than 10 repeats in this region, while FSHD1 patients have between 1 and 10 repeats.
- A minority of patients have FSHD type 2 (FSHD2), which is caused by a mechanism independent of deletion.
- Both FSHD1 and FSHD2 share a common downstream mechanism, involving loss of methylation in the D4Z4 region and the activation of a normally silenced gene, DUX4 (double homeobox 4).
- It is believed that the derepression of DUX4 leads to disease through a toxic gain-of-function mechanism.
Synonyms and related keywords: Facio-Scapulo-Humeral Dystrophy, FSH, FMD, FSHD, Muscular Dystrophy, Facioscapulohumeral, Muscular Dystrophy, Landouzy Dejerine
Facioscapulohumeral muscular dystrophy (FSHD), also known as Landouzy-Dejerine muscular dystrophy, is a neuromuscular disorder.
- Facial weakness is the initial manifestation with inability to smile, whistle, etc.
- Shoulder muscles are weak with scapular “winging” during arm abduction.
- Biceps / triceps are involved with sparing of the deltoids.
- 20% progress to involve the pelvic girdle.
- Labile hypertension, ocular involvement (Coat’s disease) and deafness can occur.
Facioscapulohumeral muscular dystrophy is usually inherited as an autosomal dominant trait. However, in up to approximately 30 percent of affected individuals, there is no apparent family history of the disorder.